Part of Postprandial Hyperglycemia
1 published article · Updated continuously
22 trials tracked for impaired glucose tolerance: 8 in phase 3 or 4 and 3 with published results. The most-cited published study has 157 citations.
Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Pharmacological interventions for impaired glucose tolerance show varied effects on glycemic markers. Exenatide was associated with a HOMA Score of 0.2 1 and was also evaluated in other studies 4. Pioglitazone demonstrated significant improvements in fasting plasma glucose over 2.4 years (-4.0 vs -10.7) 5, and when combined with exenatide, showed significant effects on body weight compared to monotherapy or placebo 3.
Metformin XR significantly improved the Insulin Secretion-Sensitivity Index (IS-SI) (418.4 vs 333; p<0.04) and fasting blood glucose (90 vs 91.7; p<0.005) 6. Dapagliflozin showed a significant reduction in fasting glucose (5.1 vs 5.9; p=0.005), though it did not significantly impact postprandial glucose or the first phase of insulin secretion 2. Subetta demonstrated a significant reduction in 2-hour plasma glucose during an OGTT (9.27 vs 8.32; p=0.0028) but did not significantly change fasting plasma glucose 7.
Lifestyle and placebo studies provide mixed results for metabolic markers. Physical activity counseling led to significant improvements in endurance (133.6 vs 112.62; p<0.001), but no significant changes were observed in fasting insulin or fasting glucose 8. Placebo groups showed significant differences in Oral Glucose Insulin Sensitivity (OGIS) (-16.0 vs 7.8; p=0.026) despite no significant change in HbA1c 19. A placebo group also showed a statistically significant difference in fasting plasma glucose (5.8 vs 5.5; p=0.004) but did not significantly impact 2-hour plasma glucose or A1C 11.
AI synthesis of 11 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
